Abstract
Introduction: In this study, we aim to analyze the effect of total body irradiation (TBI) on neutrophil and thrombocyte engraftment durations in acute leukemia (AL) patients who achieved allogeneic hematopoietic stem cell transplantation (Allo-SCT) at our center.Methods: The data of 193 acute leukemia patients who were performed Allo-SCT from matched-related donors were analyzed retrospectively.Results: Thrombocyte engraftment duration was statistically shorter (12 days) in acute lymphoblastic leukemia (ALL) patients who received TBI-based conditioning when compared to ALL patients who received non-TBI-based conditioning (14 days; p=0.037). On the other hand, no statistically significant difference was observed between acute leukemia patients who received TBI or non-TBI-based conditioning regarding neutrophil engraftment duration.Conclusion: We found that TBI had a favorable impact on thrombocyte engraftment (TE) rather than neutrophil engraftment (NE) in Allo-SCT in patients with acute leukemia. TBI might have an impact on the engraftment of thrombocytes as per than neutrophils may be attributed to immune mechanisms and microenvironment in the patient’s bone marrow (BM).
Highlights
In this study, we aim to analyze the effect of total body irradiation (TBI) on neutrophil and thrombocyte engraftment durations in acute leukemia (AL) patients who achieved allogeneic hematopoietic stem cell transplantation (Allo-SCT) at our center
We found that TBI had a favorable impact on thrombocyte engraftment (TE) rather than neutrophil engraftment (NE) in Allo-SCT in patients with acute leukemia
No statistical difference was found between acute myeloid leukemia (AML) and Acute lymphoblastic leukemia (ALL) patients regarding median NE duration (15 days, p=0.9)
Summary
We aim to analyze the effect of total body irradiation (TBI) on neutrophil and thrombocyte engraftment durations in acute leukemia (AL) patients who achieved allogeneic hematopoietic stem cell transplantation (Allo-SCT) at our center. The most frequently seen AL type is acute myeloid leukemia (AML) and it has an incidence of 5-8/100.000 [1,2]. Acute lymphoblastic leukemia (ALL) is the most frequently seen AL type in children In adults, it has an incidence of 1.28/100.000 and it is less commonly observed compared to AML [3]. Allogeneic hematopoietic stem cell transplantation (Allo-SCT) is used as a curative treatment in patients with relapsed, refractory, or high-risk acute leukemia [4,5,6]. Several risk factors have been identified for graft failure that may be related to the patient, the donor, or the transplant procedure [10]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have